# Enliven Therapeutics, Inc. (ELVN) stock price

URL: https://funkfolio.com/stock/ELVN

> Enliven Therapeutics, Inc. (ELVN) trades at $46.85 and is worth $3.45B. Valuation against its own history and up to 20 years of financials.

---

## Enliven Therapeutics, Inc. (ELVN)

Enliven Therapeutics, Inc. (ELVN) is a healthcare company (biotechnology) based in the United States. The share price is $46.85, down 1.62% on the day, which values the company at $3.45B. Price as of 17 Nov 2026, 22:24 UTC, from Yahoo Finance.

### Key facts

- **Share price:** $46.85 −1.62% today
- **Market value:** $3.45B
- **200-week average:** $24.98 88% above
- **Sector:** Healthcare

Figures as of 17 Nov 2026, 22:24 UTC. Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

### Enliven Therapeutics, Inc. in more detail

ELVN trades at -23.5× next year's expected earnings. It sits 88% above its 200-week average of $24.98.

In its favour: More cash than debt.

2 of the superinvestors tracked here hold ELVN, including Doug Silverman (0.3% of the portfolio), Julian and Felix Baker (0.2% of the portfolio).

### Superinvestors holding ELVN

2 of the investors tracked here report a position in their latest 13F filing.

- [Doug Silverman Senator Investment Group](https://funkfolio.com/gurus/doug-silverman) 0.28% of portfolio · $7.3M · new · Q3 2026
- [Julian and Felix Baker Baker Bros. Advisors](https://funkfolio.com/gurus/baker-brothers) 0.23% of portfolio · $45.9M · Q2 2026

### Enliven Therapeutics, Inc. (ELVN): questions and answers

**What is Enliven Therapeutics, Inc.'s market cap?**

Enliven Therapeutics, Inc. is valued at $3.45B at a share price of $46.85.

**Is ELVN above its 200-week moving average?**

Yes. ELVN is 87.5% above its 200-week average of $24.98. Long-term investors watch that line because strong companies rarely trade below it for long.

**Does ELVN pay a dividend?**

Enliven Therapeutics, Inc. does not currently pay a regular dividend.

**Which famous investors own ELVN?**

In their latest quarterly filings, Doug Silverman (0.3% of the portfolio), Julian and Felix Baker (0.2% of the portfolio) hold ELVN. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

### Learn to read these numbers

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- [Free cash flow and FCF yield explained](https://funkfolio.com/learn/stocks/free-cash-flow)

  Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.

### Cite this page

Funkfolio, “Enliven Therapeutics, Inc. (ELVN) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/ELVN

Underlying data: Yahoo Finance; company filings with the SEC.
